Regaining Bladder Control in Postmenopausal Women With Osteoporosis

Urinary Incontinence Clinical Trial

Official title:

Regaining Urinary Continence in Postmenopausal Women With Osteoporosis: A Randomized Controlled Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00323245
• Other study ID #: C05-0608
• Secondary ID: W05-0259
• Status: Completed
• Phase: N/A
• First received: May 8, 2006
• Last updated: April 12, 2011
• Start date: March 2006
• Est. completion date: April 2011

Study information

• Verified date: April 2011
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Conservative management for urinary incontinence has been shown to improve bladder control. We are conducting a study of the effectiveness of conservative management for urinary incontinence in women who also have osteoporosis. We hope to find that treatment for incontinence improves bladder control and thereby allows women to be more active and reduces their risk of falling and breaking bones.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

Postmenopausal women osteopenia or osteoporosis and stress urinary incontinence

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoporosis
• Urinary Incontinence

Intervention

Behavioral:
• Physiotherapy for urinary incontinence
See Detailed Description.

Locations

Country	Name	City	State
Canada	BC Womens' Health Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Incontinent Episodes (baseline and end of treatment (12 weeks)		Unspecified	No
Secondary	Urinary Distress Inventory		Unspecified	No
Secondary	Pelvic Floor Muscle Strength		Unspecified	No
Secondary	Quality of life: Each participant will complete the Incontinence Impact Questionnaire and the SF-36 at the initial and follow up measurement sessions		Unspecified	No
Secondary	Physical Activity (PASE)		Unspecified	No
Secondary	24 Hour Pad Test		Unspecified	No
Secondary	Voiding Frequency using the bladder diary		Unspecified	No
Secondary	Spinal Curvature with a flexicurve ruler		Unspecified	No
Secondary	Self-Perceived Efficacy		Unspecified	No
Secondary	All at initial and follow up (end) measurement sessions		Unspecified	No